6134-79-8

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dihydroxyacetophenone oxime is used as a chelating agent for the synthesis of pharmaceuticals. Its ability to form stable complexes with metal ions aids in the development of drugs with enhanced stability and efficacy.
Used in Dye Industry:
In the dye industry, 2,4-dihydroxyacetophenone oxime is utilized as a chelating agent to improve the colorfastness and stability of dyes. Its complexation with metal ions helps in creating dyes with better performance characteristics.
Used in Rubber Industry:
2,4-Dihydroxyacetophenone oxime is employed as a chelating agent in the rubber industry to enhance the properties of rubber products. It helps in the formation of stable complexes with metal ions, which can improve the durability and resistance of rubber materials.
Used in Analytical Chemistry:
2,4-Dihydroxyacetophenone oxime is used as a reagent for the determination of trace metals in analytical chemistry. Its chelating ability allows for the accurate measurement and analysis of metal ions in various samples.
Potential Therapeutic Use:
2,4-Dihydroxyacetophenone oxime has been studied for its potential antioxidant and anti-inflammatory properties. Its ability to neutralize free radicals and reduce inflammation may offer therapeutic benefits in the future, although further research is needed to fully understand its potential applications in this area.

InChI:InChI=1/C8H9NO3/c1-5(9-12)7-3-2-6(10)4-8(7)11/h2-4,9,11-12H,1H3/b7-5-

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 69658-70-4 1-(2,4-dihydroxy-phenyl)-ethanon-(O-acetyl oxime ) 
• 49586-28-9 1-(4-acetoxy-2-hydroxy-phenyl)-ethanone O-acetyl-oxime 
• 114594-14-8 C₁₄H₁₇NO₅ 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 66033-92-9 6-hydroxy-3-methyl-1,2-benzisoxazole 
• 76288-25-0 6-hydroxy-3-styryl-1,2-benzisoxazole 
• 76288-27-2 3-[(E)-2-(4-Methoxy-phenyl)-vinyl]-benzo[d]isoxazol-6-ol 
• 76288-33-0 8-hydroxy-1,3-dioxo-4-phenyl-1,3a,4,10b-tetrahydro-2,10-dioxa-10a-aza-3H-cyclopentafluorene 
• 76288-35-2 8-Hydroxy-4-(4-methoxy-phenyl)-3a,10b-dihydro-4H-2,10-dioxa-10a-aza-cyclopenta[a]fluorene-1,3-dione 
• 76288-39-6 7-hydroxy-3-phenyl-2,3-dihydro-1H-pyrido<1,2-b><1,2>benzisoxazole-1,2-dicarboxylic acid 
• 5078-07-9 6-hydroxy-2-methylbenzoxazole 

Relevant academic research and scientific papers

Structures and magnetism of two manganese crowns assembled with 2,4-dihydroxyacetophenone oxime

Reactions of 2,4-dihydroxyacetophenone oxime with manganese salts yielded two manganese crowns, [Mn3(μ3-O)(4-OH-Me-sao) 3(HCOO)(MeOH)5].MeOH (1) and [Mn3(μ 3-O)(4-OH-Mesao) 3(CH3

Benzoxazole compound and application thereof

The invention belongs to the field of medical treatment, and particularly relates to a benzoxazole compound and application thereof, wherein the benzoxazole compound has a compound structure as represented by a formula (A), and the compound can be used fo

Benzoisoxazole compound derivative and applications thereof

The present invention provides a benzoisoxazole compound derivative and applications thereof. According to the present invention, the in vitro receptor binding assay results show that the compound hashigh affinity to H3 receptors, can be used for improvin

7H - benzisoxazole and [7, 6 - e] [1, 3] oxazine derivative and application thereof

The invention discloses 7H-benzo-isoxazole-[7,6-e][1,3]oxazine derivatives as shown in the formula I or pharmaceutically acceptable hydrates/salts thereof, and further discloses stereoisomers or tautomers of the 7H-benzo-isoxazole-[7,6-e][1,3]oxazine deri

Natural products as sources of new fungicides (II): antiphytopathogenic activity of 2,4-dihydroxyphenyl ethanone derivatives

A series of 17 simple 1-(2,4-dihydroxyphenyl) ethanones were synthesised, and their structures characterised by 1H, 13C NMR and ESI-MS. Their in vitro antifungal activities were evaluated against five phytopathogenic fungi including Glomerella cingulate, Botrytis cirerea, Fusarium graminearum, Curvularia lunata and Fusarium oxysporum f. sp. vasinfectum by the mycelial growth inhibition assay. Compounds 2g and 2h exhibited broad-spectrum inhibitory activity against the mycelial growth of the tested pathogens with IC50 values in the range of 16-36 g/mL, and in particular being more active to G. cingulate, with IC50 values of 16.50 and 19.25 g/mL, respectively, than the other pathogens. Preliminary SAR indicated that an α,β-unsaturated ketone unit of the alkyl chain of the compounds is the structure requirement for fungicidal action. The results suggested that 2g and 2h may be promising leads in the development of new antifungal agents.

IRE-1α INHIBITORS

PROBLEM TO BE SOLVED: To provide compounds which directly inhibit inositol requiring enzyme 1 (IRE-1α activity) in vitro, prodrugs, and pharmaceutically acceptable salts thereof. SOLUTION: The present invention provides a compound represented by formula (A) [R3 and R4 are H or the like; Q5-Q8, together with the benzene ring to which they are attached, form a benzofused ring, where at least one of Q5-Q8 is a heteroatom selected from N, O, and S. COPYRIGHT: (C)2016,JPOandINPIT

Development of a multikilogram synthesis of a chiral epoxide precursor to a CCR1 antagonist. Use of in situ monitoring for informed optimisation via fragile intermediates

The optimisation and scale up of a manufacturing route to a key intermediate, acetic acid 4-acetylamino-3-(2-methyl-oxiranyl- methoxy)phenyl ester (2), utilising a SNAr coupling, the hydro- genation of a nitro moiety and the conversion of a chi

BENZISOXAZOLE COMPOUND

Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: -(CH2)m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: -(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.

CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF

The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure: Formula (I).

Synthesis of New Isoxazoles from Isoxazolines, Chalkones, Chalkone Dibromides, Epoxides and Acetylated Ketoximes and Their Conversion into Novel Heterocycles

A convenient and easy conversion of 2-isoxazolines (II) to isoxazoles (V) via N-bromosuccinimide bromination and subsequent dehydrobromination with bases is described.The isoxazoles have also been synthesized from chalkones (I), chalkone dibromides (III)